Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
1. Illumina’s board gains Keith Meister from Corvex Management on March 28. 2. Past challenges included the costly Grail acquisition and geopolitical issues. 3. Illumina dominates 80% of the gene-sequencing market despite recent struggles. 4. Transition to NovaSeq X may create short-term revenue pressure but could spur growth. 5. Company's value has significantly dropped from $70 billion to under $13 billion.